Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officer

Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.

Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global Scientific Affairs at Bausch + Lomb, overseeing the medical and clinical development of the company's surgical portfolio.

"Dr. Kolesnitchenko has a strong foundation in both surgical and therapeutic ophthalmology, as well as highly developed interpersonal skills and industry relationships," Dr. AnnMarie Hipsley, CEO of Ace Vision Group, said in a company news release. "He has an impressive record of effectively connecting with cross-functional team members to facilitate clinical studies and advising on device regulatory and technical requirements. Val's assignment to the company as Chief Scientific Officer comes at a very timely period in the company's preparations for its  medical device regulatory submissions. We are very excited to have such a seasoned C-suite executive on board."

At Ace Vision Group, Dr. Kolesnitchenko will apply his insight and skills to the VisioLite laser device, the company's flagship technology used for the Laser Scleral Microporation (LSM) therapy. LSM is designed to restore the eye's natural dynamic range of focus (DRoF), allowing patients to see clearly at all distances with the eye's natural functionality. The VisioLite Ophthalmic Laser System & LSM are not yet FDA approved or available in the United States. 

"I look forward to working with Ace Vision Group on this revolutionary approach to presbyopia," said Dr. Kolesnitchenko. "LSM can treat the progressive problem throughout the lifecycle of this disease, opening new doors for treatment of the aging eye, and I am excited to lead a team as we research and communicate the fascinating science behind this therapy."